MINJUVI DIN 02518627
Health Canada record
| Active ingredient(s) | TAFASITAMAB 200 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L01FX12 TAFASITAMAB |
| Original market date | 06-Dec-2021 |
| Current status date | 06-Dec-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Incyte Biosciences Technical Operations S.a.r.l. — licence , not currently licensed, last inspection rating C (2024-07-26).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26490 | 2021-08-19 | New Drug Submission (NDS) |